Related Experiment Videos
Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist
J T Lazzaro1, A V Paternain, J Lerma
1CNS Discovery, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
Neuropharmacology
|January 24, 2002
Summary
A novel quinazolin-4-one antagonist, CP-465,022, effectively inhibits alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activity. This compound shows selectivity and offers a new tool for studying AMPA receptors in neurological conditions.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Aberrant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activity is implicated in epileptogenesis and neurodegeneration.
- Developing AMPA receptor antagonists is a therapeutic strategy for these neurological conditions.
Purpose of the Study:
- To functionally characterize a novel quinazolin-4-one AMPA receptor antagonist, CP-465,022.
- To evaluate the compound's potency, selectivity, and mechanism of action.
- To assess its utility as a research tool.
Main Methods:
- Functional characterization of CP-465,022 in rat cortical neurons.
- Electrophysiological recordings to measure AMPA receptor-mediated currents.
- Assays to determine IC(50) values and assess selectivity against kainate and N-methyl-D-aspartate receptors.
- Evaluation of inhibition characteristics (noncompetitive, use- and voltage-independence).
Main Results:
- CP-465,022 inhibits AMPA receptor-mediated currents with an IC(50) of 25 nM.
- Inhibition is noncompetitive, and not use- or voltage-dependent.
- CP-465,022 demonstrates selectivity for AMPA receptors over kainate and N-methyl-D-aspartate receptors.
- The compound is equipotent across different AMPA receptor subunit combinations.
Conclusions:
- CP-465,022 is a potent and selective noncompetitive antagonist of AMPA receptors.
- It functions independently of agonist concentration, use, and voltage.
- CP-465,022 serves as a valuable new pharmacological tool for investigating AMPA receptor roles in physiological and pathophysiological processes, including epilepsy and neurodegeneration.